Floatz logo

Ipilimumab

Pulmonary Metastases

Masonic Cancer Center, University of Minnesotamonoclonal_antibodyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Pulmonary Metastases cohort.

Asset / SponsorPhaseRating
su011248
Association of Urologic Oncology (AUO)
Phase 2CCC
5-azacytidine
National Cancer Institute (NCI)
Phase 1/2CC
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
National Cancer Institute (NCI)
Phase 1/2CC
Carboplatin
Sun Yat-sen University
N/AD
Irinotecan
Sun Yat-sen University
N/AD
(+)-VINCRISTINE
Sun Yat-sen University
N/AD

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →